Literature DB >> 2106954

Interleukin 2.

T J Hamblin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2106954      PMCID： PMC1661905          DOI： 10.1136/bmj.300.6720.275

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  13 in total

1.  Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

Authors:  M S Mitchell; R A Kempf; W Harel; H Shau; W D Boswell; S Lind; E C Bradley
Journal:  J Clin Oncol       Date:  1988-03       Impact factor: 44.544

2.  Cancer M.D.'s clash over interleukin therapy.

Authors:  M Bloom
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

3.  On lymphokines, cytokines, and breakthroughs.

Authors:  C G Moertel
Journal:  JAMA       Date:  1986-12-12       Impact factor: 56.272

4.  Mechanism of cultured endothelial injury induced by lymphokine-activated killer cells.

Authors:  D Kotasek; G M Vercellotti; A C Ochoa; F H Bach; J G White; H S Jacob
Journal:  Cancer Res       Date:  1988-10-01       Impact factor: 12.701

5.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

Authors:  S A Rosenberg; M T Lotze; L M Muul; S Leitman; A E Chang; S E Ettinghausen; Y L Matory; J M Skibber; E Shiloni; J T Vetto
Journal:  N Engl J Med       Date:  1985-12-05       Impact factor: 91.245

6.  Nephrotoxicity of continuous intravenous infusion of recombinant interleukin-2.

Authors:  N P Christiansen; K M Skubitz; K Nath; A Ochoa; B J Kennedy
Journal:  Am J Med       Date:  1988-06       Impact factor: 4.965

7.  The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells.

Authors:  K D Denicoff; D R Rubinow; M Z Papa; C Simpson; C A Seipp; M T Lotze; A E Chang; D Rosenstein; S A Rosenberg
Journal:  Ann Intern Med       Date:  1987-09       Impact factor: 25.391

8.  Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.

Authors:  W H West; K W Tauer; J R Yannelli; G D Marshall; D W Orr; G B Thurman; R K Oldham
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

9.  Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells.

Authors:  M B Atkins; J W Mier; D R Parkinson; J A Gould; E M Berkman; M M Kaplan
Journal:  N Engl J Med       Date:  1988-06-16       Impact factor: 91.245

10.  Induction and detection of a human endothelial activation antigen in vivo.

Authors:  R S Cotran; M A Gimbrone; M P Bevilacqua; D L Mendrick; J S Pober
Journal:  J Exp Med       Date:  1986-08-01       Impact factor: 14.307
View more
  5 in total

1.  Immunological response in chronic fatigue syndrome following a graded exercise test to exhaustion.

Authors:  J J LaManca; S A Sisto; X D Zhou; J E Ottenweller; S Cook; A Peckerman; Q Zhang; T N Denny; W C Gause; B H Natelson
Journal:  J Clin Immunol       Date:  1999-03       Impact factor: 8.317

2.  Medicine in Europe. European health challenges.

Authors:  T Smith
Journal:  BMJ       Date:  1991-11-30

Review 3.  Prophylaxis against non-steroidal induced upper gastrointestinal side effects.

Authors:  I Barrison
Journal:  Ann Rheum Dis       Date:  1991-04       Impact factor: 19.103

4.  Interleukin 2.

Authors: 
Journal:  BMJ       Date:  1990-03-17

5.  Spinal fluid abnormalities in patients with chronic fatigue syndrome.

Authors:  Benjamin H Natelson; Shelley A Weaver; Chin-Lin Tseng; John E Ottenweller
Journal:  Clin Diagn Lab Immunol       Date:  2005-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.